- Home
- AVTX vs RA Comparison
AVTX vs RA Comparison
Compare AVTX & RA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVTX | RA |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | 33 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 710.1M | 712.8M |
| IPO Year | 2015 | 2016 |
Fundamental Metrics
Financial Performance| Metric | AVTX | RA |
|---|---|---|
| Price | $12.14 | $11.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $44.08 | N/A |
| AVG Volume (30 Days) | ★ 959.1K | 322.5K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,813,137.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2312.27 | N/A |
| 52 Week Low | $12.51 | $11.41 |
| 52 Week High | $24.27 | $13.59 |
Technical Indicators
Market Signals| Indicator | AVTX | RA |
|---|---|---|
| Relative Strength Index (RSI) | 22.50 | 35.12 |
| Support Level | N/A | N/A |
| Resistance Level | $20.54 | $12.97 |
| Average True Range (ATR) | 0.84 | 0.14 |
| MACD | -0.17 | 0.02 |
| Stochastic Oscillator | 1.24 | 24.75 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
About RA Brookfield Real Assets Income Fund Inc.
Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. The investment objective of the Fund is to seek high total return, through high current income and secondarily, through growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities, Infrastructure Securities, and Natural Resources Securities. The Fund operates in a single operating segment.